Vireo Growth Completes Strategic Pennsylvania Dispensary License Acquisition

Vireo Growth Inc. (CSE: VREO, OTCQX: VREOF), a prominent vertically integrated cannabis company, announced the completion of its $20 million acquisition of the Pennsylvania medical cannabis dispensary license interests of FarmX, LLC, in conjunction with Vive Penn LLC. This strategic acquisition is set to expand Vireo Growth's operations to its 11th U.S. state, marking its entry into one of the country's significant medical cannabis markets.

The transaction, which closed on July 17, 2026, was conducted under a previously announced Securities Purchase Agreement (SPA). Under the terms of the agreement, all issued and outstanding limited liability company membership interests of FarmX, LLC d/b/a PhytoNatural were acquired by Vive Penn, a joint venture between Vireo Growth and Hive Holdings, Inc. This acquisition includes a non-operational Pennsylvania medical cannabis retail permit that, subject to applicable regulatory approvals, authorizes the operation of up to six dispensaries in the Commonwealth.

The total consideration for the transaction amounted to $20.0 million. An $8.0 million cash component was paid by Vive Penn at closing. The remaining approximately $12.0 million will be satisfied through the issuance of approximately 645,161 Vireo subordinate voting shares, valued at a deemed price of $18.60 per share, to be issued two years following the closing date. This payment structure reflects a strategic approach to capital allocation.

This acquisition is part of Vireo Growth's broader effort to strengthen its presence in the rapidly expanding U.S. medical cannabis markets. Pennsylvania, with approximately 450,000 registered patients and ranking as the fifth most populous state, presents an attractive medical cannabis market. The company believes it is well-positioned to establish a significant presence in the state. Previously, upon the announcement of this deal on July 2, 2026, Vireo Growth's subordinate voting shares (VREOD) saw a 4.08% increase, indicating a positive market reaction to the news. However, the company's stock price has recently faced headwinds, trading at $9.80 and down 45% year-to-date, possibly due to broader market conditions or other factors.

The cannabis industry in the U.S. operates within a complex regulatory landscape, characterized by diverse state-level regulations and federal uncertainty. While medical cannabis programs are legalized in many states, cannabis remains federally illegal. This necessitates companies in the sector to meticulously plan their operations and growth strategies on a state-by-state basis. Vireo Growth's entry into limited-license markets like Pennsylvania demonstrates its strategic positioning within this regulatory environment, offering long-term growth potential. Such expansions, as state-level legal frameworks mature, could accelerate consolidation and institutionalization within the industry.

Vireo Growth CEO John Mazarakis stated that Pennsylvania is an attractive medical market and this transaction provides them with an entry into the state through the ability to operate up to six dispensaries. The company is evaluating sites for the Vive retail stores and believes it is well-positioned to build a meaningful presence in one of the country's leading limited-license cannabis markets. Analysts suggest that such strategic acquisitions support Vireo Growth's objective to increase market share and strengthen its portfolio of consumer brands. InvestingPro analysis indicates that despite recent pressures, the stock is undervalued relative to its Fair Value, with analysts projecting profitability this year after recent losses. This outlook supports optimistic expectations for the company's future performance.